** Shares in Chr Hansen CHRH.CO jump 11% after the Danish
food ingredients maker reports slightly better-than-expected Q4
results and announces consensus-beating 2022/23 revenue guidance
urn:newsml:reuters.com:*:nFWN31D00T
** The company sees full-year revenue growth in the range of
7-10% and expects revenue to be positively impacted by about 5%
from exchange rates
** It forecasts EBIT to grow faster than revenue, and EBIT
margin before special items to be in range of 27.0%-28.0%
** J.P. Morgan notes Chr Hansen's growth guidance is 6.6%
ahead of consensus, while adj. EBIT margins outlook meets market
expectations and beats JPM's own estimate
** "We expect share price support on the result," the
brokerage says
** It adds the quarter should reassure along with
management's FY23 guidance, though remains cautious on the
pricing and demand environment
** Shares of Chr Hansen are on track for their best day in
10 years and jump to the top of STOXX 600 index .STOXX
** Shares in Danish peer Novozymes NZYMb.CO rise 3.4% in
Wednesday's morning trade
(Reporting by Agnieszka Gosciak-Rabalska)
((agnieszka.gosciak@thomsonreuters.com))